Neuphoria Therapeutics has been growing earnings at an average annual rate of 7%, while the Biotechs industry saw earnings growing at 36.2% annually. Revenues have been growing at an average rate of 49.9% per year.
How Neuphoria Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
NasdaqGM:NEUP Revenue, expenses and earnings (USD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
0
-17
8
7
31 Dec 25
15
-6
7
9
30 Sep 25
16
-9
8
11
30 Jun 25
16
0
8
9
31 Mar 25
16
6
8
8
31 Dec 24
1
-8
8
13
30 Sep 24
0
-11
8
11
30 Jun 24
0
-15
8
9
31 Mar 24
0
-18
9
13
31 Dec 23
0
-20
11
13
30 Sep 23
0
-22
10
13
30 Jun 23
0
-21
9
13
31 Mar 23
2
-19
7
6
31 Dec 22
4
-17
5
0
30 Sep 22
4
-15
5
0
30 Jun 22
4
-15
5
0
31 Mar 22
2
-16
6
0
31 Dec 21
0
-16
6
0
30 Sep 21
1
-11
5
0
30 Jun 21
1
-7
4
0
31 Mar 21
1
-3
4
0
31 Dec 20
1
1
4
0
30 Sep 20
2
-2
4
0
30 Jun 20
2
-4
3
0
31 Dec 19
4
-3
4
0
30 Sep 19
5
-5
4
0
30 Jun 19
5
-7
6
0
31 Mar 19
6
-14
8
0
31 Dec 18
5
-20
8
0
30 Sep 18
7
-19
8
0
30 Jun 18
9
-19
8
0
31 Mar 18
15
-12
7
0
31 Dec 17
21
-5
6
0
30 Sep 17
21
-5
6
0
30 Jun 17
21
-5
6
0
31 Mar 17
17
-9
8
0
31 Dec 16
12
-12
9
0
30 Sep 16
14
-13
9
0
30 Jun 16
14
-12
8
0
31 Mar 16
14
-14
8
0
31 Dec 15
13
-15
7
0
30 Sep 15
12
-13
6
0
30 Jun 15
12
-13
7
0
Quality Earnings: NEUP is currently unprofitable.
Growing Profit Margin: NEUP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NEUP is unprofitable, but has reduced losses over the past 5 years at a rate of 7% per year.
Accelerating Growth: Unable to compare NEUP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NEUP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).
Return on Equity
High ROE: NEUP has a negative Return on Equity (-59.24%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/21 13:03
End of Day Share Price
2026/06/18 00:00
Earnings
2026/03/31
Annual Earnings
2025/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neuphoria Therapeutics Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.